Financials in USD. Standardized financial statements.
A compact view of how Aquestive Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M | $45.85M | $52.61M | $67.43M | $66.92M | $51.78M |
| Revenue Growth? | -22.6% | +13.8% | +6.1% | -6.2% | +10.9% | -12.8% | -22.0% | +0.8% | +29.2% | 0.0% |
| Cost of Revenue? | $17.15M | $17.87M | $20.83M | $19.39M | $14.99M | $12.96M | $20.36M | $20.99M | $19.82M | $16.38M |
| Gross Profit? | $27.39M | $39.69M | $29.75M | $28.29M | $35.84M | $32.88M | $32.25M | $46.44M | $47.10M | $35.41M |
| Gross Margin? | +61.5% | +69.0% | +58.8% | +59.3% | +70.5% | +71.7% | +61.3% | +68.9% | +70.4% | +68.4% |
| Operating Expenses? | $97.04M | $70.46M | $44.85M | $70.36M | $70.52M | $75.78M | $84.92M | $95.38M | $47.21M | $36.25M |
| Operating Income? | -$69.65M | -$30.77M | -$15.10M | -$42.07M | -$34.68M | -$42.89M | -$52.67M | -$48.93M | -$113,000 | -$847,000 |
| EBITDA? | -$69.09M | -$26.62M | $1.18M | -$39.58M | -$45.11M | -$39.15M | -$53.88M | -$50.33M | $2.56M | $2.94M |
| Income Before Tax | -$83.78M | -$44.15M | -$7.63M | -$54.41M | -$70.54M | -$55.78M | -$66.25M | -$61.38M | -$8.94M | -$9.60M |
| Income Tax Expense | $0 | -$14,000 | $245,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M | -$55.78M | -$66.25M | -$61.38M | -$8.94M | -$9.60M |
| EPS? | $-0.76 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | $-2.87 | $-2.96 | $-0.45 | $-0.39 |
| Diluted EPS? | $-0.76 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | $-2.87 | $-2.96 | $-0.45 | $-0.39 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality